Cargando…
Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status
BACKGROUND: Intravenous iron replacement is recommended for iron-deficient patients with inflammatory bowel disease (IBD), but may be associated with hypophosphataemia, predisposing to osteomalacia and fractures. This study aimed to evaluate the incidence and risk factors for hypophosphataemia follo...
Autores principales: | Fang, Wendy, Kenny, Rachel, Rizvi, Qurat-ul-Ain, McMahon, Lawrence P., Garg, Mayur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288415/ https://www.ncbi.nlm.nih.gov/pubmed/32522150 http://dx.doi.org/10.1186/s12876-020-01298-9 |
Ejemplares similares
-
Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose
por: Fang, Wendy, et al.
Publicado: (2019) -
Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials
por: Rosano, Giuseppe MC, et al.
Publicado: (2023) -
A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose
por: Rosano, Giuseppe, et al.
Publicado: (2020) -
Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis
por: Schaefer, Benedikt, et al.
Publicado: (2020) -
Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial
por: Zoller, Heinz, et al.
Publicado: (2023)